Robert Peter Gale, MD, PhD, DSc, FACP, FRCP, FRCPI, FRSM, Imperial College London, London, UK, shares his perspectives on the status of hematopoietic cell transplantation in chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs). The introduction of TKIs has led to a substantial decrease in the number of patients with CML undergoing transplantation. However, Prof. Gale argues that transplantation is still a viable option in many patients due to the low rate of patients achieving treatment-free remission (TFR) and due to the financial toxicity of lifelong TKI therapy. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
You can find more information here: https://pubmed.ncbi.nlm.nih.gov/35338251/
Consultant to NexImmune Inc., Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC; Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisor